本实验室依托本北京大学公共卫生学院，整合了北京大学公众健康与重大疫情防控战略研究中心、北京大学临床医学高等研究院、北京大学第一医院和第三医院等多方优势力量建立。作为国家科技创新体系的关键单元及高等院校创新型人才培养的核心基地，实验室聚焦 “人群健康与重大疾病” 的国家战略需求，于2023年成功获批建设，并于2025年顺利召开验收会议。实验室以学术委员会指导下的主任负责制、实验室主任领导下的 PI 负责制为管理模式，构建了科学合理的研究方向布局、结构优化的研究团队体系及切实可行的运行管理机制，并具备优良的科研条件支撑，在学科建设、科技创新、人才培养及国家级科研基地培育中发挥战略性支撑作用。

实验室以具有公共卫生学重要意义的重大慢性病与传染病为研究对象，重点聚焦四大研究方向：慢性病流行病学、循证医学与临床流行病学、卫生统计学与数据科学、传染病流行病学。以实现人群为基础的重大疾病科学防控、促进公众健康为核心使命，以流行病学为核心研究方法，以公共卫生数字化转型为发展导向，以循证评价与决策为支撑体系，开展系列创新性研究，服务“健康中国”国家战略。

目前，实验室固定成员57人，其中高级职称人员45人（正高级23人，副高级22人），现有欧亚科学院院士1名，英国皇家内科医学院公共卫生学院荣誉院士（HonFFPH）和院士（FTD）各1名，“吴阶平-保罗·杨森医学药学奖”获得者2名，“万人计划”科技创新领军人才2名和教学名师2名，长江特岗学者1名，长江青年学者1名，国家优秀青年科学基金获得者3名，海外优青2名，“千人计划”青年人才1名。2024-2025年间，团队28人次入选2025年度全球前2%顶尖科学家榜单，30人入选2024中国知网高被引学者名单。

实验室现有科研与办公面积约6700m2，于2025年启用异地实体科研机构——北京大学鄞州数智健康联合研究院。现有仪器设备总价值5651万元，建有完备的实验室检测平台、生物样本库及高性能计算集群，为承担国家重大科研任务提供了坚实支撑。

实验室具有国内顶尖、国际先进的人群研究创新基础平台，既包括大规模自然人群队列，如国际领先的51.3万人的成人队列、宁波市鄞州区105万自然人群队列；也有特殊人群队列，如6万余对双生子队列、房山家系队列、福建土楼家系队列、以及覆盖全国的健康体检人群大数据等，具有促进多学科、跨领域科技创新的优势资源平台。

实验室近年来多项病因学研究证据影响了我国慢性病预防指南的制/修订，致力于开发中国心血管预防综合干预技术、形成中国减盐方案，促进临床研究证据融合的科学性、规范性，助力循证决策，研究团队提出和发展大数据驱动的流行病学与卫生统计学方法，在N Engl J Med，Lancet，JAMA，BMJ等国际知名医学期刊发表多项科研成果。自成立至2025年底，累计发表600余篇论文于国内外知名期刊，其中高影响因子文章100余篇；新增科研项目50余项，其中国家自然科学基金13项。

机构负责人：詹思延

联系人：余灿清

邮箱：yucanqing@bjmu.edu.cn

电话：010-82801528-342

地址：北京市海淀区学院路38号

网址链接：https://klemd.pku.edu.cn/

Key Laboratory of Epidemiology of Major Diseases(Peking University) , Ministry of Education

This laboratory is established based on Peking University School of Public Health, integrating the strengths of multiple institutions including Peking University Center for Public Health and Epidemic Preparedness&Response, Peking University Institute of Advanced Clinical Medicine, Peking University First Hospital, and Peking University Third Hospital. As a key component of the national science and technology innovation system and a core base for cultivating innovative talents in institutions of higher learning, the laboratory focuses on the national strategic needs of "population health and major diseases". It was successfully approved for construction in 2023 and held a smooth acceptance meeting in 2025. Operating under a director responsibility system guided by an academic committee and a PI (Principal Investigator) responsibility system led by the laboratory director, it has established a scientifically sound research framework, an optimized team structure, and a robust operational management mechanism. Supported by excellent research facilities, the laboratory plays a strategic and supportive role in discipline advancement, scientific and technological innovation, talent cultivation, and the development of national-level research bases.

The laboratory targets major chronic diseases and infectious diseases of great public health significance, focusing on four key research areas: chronic disease epidemiology, evidence-based medicine and clinical epidemiology, health statistics and data science, and infectious disease epidemiology. With the core mission of achieving population-based scientific prevention and control of major diseases and promoting public health, it takes epidemiology as the core research method, public health digital transformation as the development orientation, and evidence-based evaluation and decision-making as the supporting system to carry out a series of innovative research and serve the national strategy of "Healthy China".

The laboratory currently has 57 permanent members, including 45 senior researchers (23 professors and 22 associate professors). Among them, there is one academician of the Eurasian Academy of Sciences, one honorary fellow (HonFFPH) and one fellow (FTD) of the Faculty of Public Health at the Royal College of Physicians of the United Kingdom, two recipients of the "Wu Jieping-Paul Janssen Award for Medical and Pharmaceutical Sciences," two National High-Level Talents Special Support Program (also known as the "Ten Thousand Talents Program") leading innovators, two distinguished teaching experts, one Cheung Kong Scholar (special-term professor), one Cheung Kong Young Scholar, three recipients of the National Science Fund for Excellent Young Scholars, two recipients of the Overseas Young Scholars Program, and one recipient of the "Thousand Talents Program" for young talents. Between 2024 and 2025, a total of 28 team members were included in the "World's Top 2% Scientists" list, and 30 were recognized in the 2024 China National Knowledge Infrastructure (CNKI) Highly Cited Researchers list, reflecting the team's significant academic influence.

The laboratory boasts a combined research and office area of approximately 6,700 square meters. In 2025, an off-site physical research facility—Peking university - Yinzhou Regional joint institute for Advanced Medical Intelligence and Digital health(PYRAMID)—was established. The laboratory is equipped with instruments and facilities valued at approximately 56.51 million yuan, including a fully functional experimental testing platform, a biobank, and a high-performance computing cluster. This infrastructure provides solid support for undertaking major national research projects.

The laboratory has a domestically leading and internationally advanced population research innovation platform. It includes large-scale natural population cohorts, such as the internationally leading 513,000-person adult cohort and the 1.05 million-person natural population cohort in Yinzhou District, Ningbo. It also encompasses special population cohorts, including over 60,000 twin pairs, the Fangshan family cohort, the Fujian Tulou family cohort, and a national big-data platform for health screening populations. These resources provide a strong foundation for fostering multidisciplinary and cross-sector scientific innovation.

In recent years, multiple etiological research findings from the laboratory have influenced the formulation and revision of China's chronic disease prevention guidelines. It is dedicated to developing comprehensive intervention technologies for cardiovascular disease prevention in China, formulating national salt reduction strategies, enhancing the scientific rigor and standardization of clinical evidence integration, and facilitating evidence-informed policymaking. The research team has proposed and developed big data-driven epidemiological and health statistics methods, and published numerous research results in internationally renowned medical journals such as The New England Journal of Medicine, The Lancet, JAMA, and The BMJ. From its inception through the end of 2025, it has published more than 600 papers in well-known domestic and foreign journals, including over 100 high-impact-factor articles. More than 50 new scientific research projects have been added, including 13 grants from the National Natural Science Foundation of China. Remarkable achievements have been made in talent team development: 28 researchers were named to the 2025 list of the World's Top 2% Scientists, and 30 were included in the 2024 list of Highly Cited Chinese Researchers by CNKI.

Director: Siyan Zhan

Contact: Canqing Yu

Email: yucanqing@bjmu.edu.cn

TEL: 010-82801528-342

Address: 38 Xueyuan Road, Haidian District, Beijing

Website: https://klemd.pku.edu.cn/